Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

Galapagos to pay up to $27 million in upfront and preclinical milestone payments to BridGene

08-Jan-2024 - Galapagos NV announced that it has entered into a strategic collaboration and licensing agreement with BridGene Biosciences, Inc. (“Bridgene”), a biotechnology company that uses proprietary chemoproteomics technology to discover novel small molecule drug candidates. Through this collaboration, ...

Servier and Galapagos initiate strategic alliance for innovative treatments in oncology

Joint discovery and development of novel small molecule therapies for cancer

11-Oct-2011 - Servier and Galapagos NV announced that they have entered into a multi-year strategic alliance to develop new cancer therapies. The alliance builds on a combination of novel Galapagos and Servier targets in oncology. Galapagos will be responsible for the discovery and development of new ...

Galapagos delivers validated oncology targets to Janssen

26-Apr-2011 - Galapagos NV announced that its BioFocus service division has delivered a panel of validated oncology targets in its collaboration with Janssen Research & Development, a division of Janssen Pharmaceutica N.V. (Janssen). Per the agreement, Janssen retains full rights to discover, develop and ...

Galapagos discontinues Phase II trial for GLPG0259, focuses resources on other rheumatoid arthritis programs

19-Apr-2011 - Galapagos NV announced that it will discontinue its Phase II clinical trial for GLPG0259 in rheumatoid arthritis. This decision is based on the outcome of a planned interim analysis which did not support the continuation of GLPG0259's development for rheumatoid arthritis. An Interim Review ...

Galapagos and the National Cancer Institute sign compound management agreement

13-Oct-2010 - Galapagos NV announced that the Compound Focus subsidiary of its BioFocus service division has signed an agreement with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH). Under the terms of the agreement, BioFocus will provide compound management services ...

Galapagos' affiliate Argenta and Janssen Pharmaceutica enter in integrated cancer drug discovery service agreement

05-Oct-2010 - Galapagos NV announced that its affiliate, Argenta Discovery 2009 Limited, has entered into a drug discovery service agreement with Janssen Pharmaceutica N.V. (Janssen), aimed at delivering novel cancer drug candidates. Argenta will provide medicinal chemistry and biology for a number of Janssen ...

Galapagos and University of Bristol enter drug discovery collaboration in chronic pain

20-Jul-2010 - Galapagos NV and the University of Bristol announced a new drug discovery collaboration aimed at developing treatments for chronic pain associated with diabetes (diabetic neuropathic pain). Galapagos' service division BioFocus will provide hit-to-lead and lead optimization services for a ...

Galapagos and GlaxoSmithKline broaden arthritis alliance

Expansion of programs based on promising drug target GT622 €6.5 M payment this year and additional milestones

17-Dec-2009 - Galapagos NV announced that it has expanded its arthritis alliance with GlaxoSmithKline to include additional drug discovery programs based on novel drug target GT622. Under the terms of this extension, Galapagos will receive a payment from GSK of €6.5 million cash and becomes eligible for ...

BioFocus DPI and Oncodesign forge alliance to provide integrated oncology drug discovery services

28-Jul-2009 - BioFocus DPI and Oncodesign announced that they have joined forces to offer a comprehensive oncology drug discovery service. The alliance combines BioFocus DPI’s target discovery and screening capabilities with Oncodesign’s experimental pharmacological and biomarker expertise in oncology. In ...

Galapagos delivers second pre-clinical candidate in alliance with GlaxoSmithKline

Galapagos receives €5.2 million in milestone payments

08-Jul-2009 - Galapagos NV announced that it has successfully identified a second pre-clinical candidate compound in its osteoarthritis alliance with GlaxoSmithKline (GSK). Galapagos also reached a milestone on another compound in the alliance. Together these milestones trigger payments totaling €5.2 million ...